Linagliptin, classified as a potent DPP4 inhibitor [98], may mitigate cerebral vascular pathology associated with T2D and other diseases related to abnormal vascular formation, potentially slowing or inhibiting brain disorder progression [99]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.